In randomized controlled trials (RCTs), two PCSK9 inhibitors, alirocumab and evolocumab, have shown encouraging results in preventing major vascular events in high-risk ASCVD patients compared to placebo (Giugliano et al., 2017b; Sabatine et al., 2017; Schwartz et al., 2018; Szarek et al., 2019). This evidence concerns the gene PCSK9 and atherosclerosis.